<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680248</article-id><article-id pub-id-type="doi">10.3390/v16121815</article-id><article-id pub-id-type="publisher-id">viruses-16-01815</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Challenges in Global Distribution and Equitable Access to Monkeypox Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1723-1350</contrib-id><name><surname>Danladi</surname><given-names>Nengak P.</given-names></name><xref rid="af1-viruses-16-01815" ref-type="aff">1</xref><xref rid="af2-viruses-16-01815" ref-type="aff">2</xref><xref rid="c1-viruses-16-01815" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Agboola</surname><given-names>Progress</given-names></name><xref rid="af3-viruses-16-01815" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6001-3899</contrib-id><name><surname>Olaniyi</surname><given-names>Peter</given-names></name><xref rid="af3-viruses-16-01815" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-6059-8390</contrib-id><name><surname>Eze</surname><given-names>Solomon</given-names></name><xref rid="af4-viruses-16-01815" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-8718-9289</contrib-id><name><surname>Oladapo</surname><given-names>Oluwatimilehin</given-names></name><xref rid="af5-viruses-16-01815" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Obiwulu</surname><given-names>Danielle</given-names></name><xref rid="af6-viruses-16-01815" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Akano</surname><given-names>Olatokun Shamsudeen</given-names></name><xref rid="af5-viruses-16-01815" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Adeola</surname><given-names>Olowoyeye Aishat</given-names></name><xref rid="af7-viruses-16-01815" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-2644-9651</contrib-id><name><surname>Olawale</surname><given-names>Khaliq</given-names></name><xref rid="af8-viruses-16-01815" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4885-4323</contrib-id><name><surname>Adiatu</surname><given-names>Azeez Idowu</given-names></name><xref rid="af9-viruses-16-01815" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Peace</surname><given-names>Agboola</given-names></name><xref rid="af10-viruses-16-01815" ref-type="aff">10</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Schwartz</surname><given-names>David A.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Colebunders</surname><given-names>Robert</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Katoto</surname><given-names>Patrick</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Grose</surname><given-names>Charles</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01815"><label>1</label>Global Health Infectious Diseases and Control Institute, Nasarawa State University Keffi, RWR4+H9P, Keffi 961101, Nigeria</aff><aff id="af2-viruses-16-01815"><label>2</label>African Community for Systematic Review and Meta-Analysis, 172 Akai Efa, MCC Road, Calabar 540211, Cross River State, Nigeria</aff><aff id="af3-viruses-16-01815"><label>3</label>Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso 210214, Nigeria; <email>agboolaprogress@gmail.com</email> (P.A.); <email>peterolaniyi17@gmail.com</email> (P.O.)</aff><aff id="af4-viruses-16-01815"><label>4</label>Department of Biochemistry, Abia State University, Uturu 441103, Nigeria; <email>chaplainsolomoneze@gmail.com</email></aff><aff id="af5-viruses-16-01815"><label>5</label>College of Medicine, University of Ibadan, Ibadan 200001, Nigeria; <email>timmidapo@gmail.com</email> (O.O.); <email>olatokunshamsudeen@gmail.com</email> (O.S.A.)</aff><aff id="af6-viruses-16-01815"><label>6</label>College of Medicine, University of Lagos, Lagos 102216, Nigeria; <email>danielleobiwulu@gmail.com</email></aff><aff id="af7-viruses-16-01815"><label>7</label>College of Health Sciences, Obafemi Awolowo University, Ile-Ife 220103, Nigeria; <email>flowergeal56@gmail.com</email></aff><aff id="af8-viruses-16-01815"><label>8</label>Department of Medical Rehabilitation, College of Health Sciences, Obafemi Awolowo University, Ile-Ife 220103, Nigeria; <email>olawalekhaliq@gmail.com</email></aff><aff id="af9-viruses-16-01815"><label>9</label>Faculty of Pharmacy, University of Ibadan, Ibadan 200001, Nigeria; <email>adiatuazeez310@gmail.com</email></aff><aff id="af10-viruses-16-01815"><label>10</label>Seventh-Day Adventist College of Nursing, Ile-Ife 220103, Nigeria; <email>peaceagboola60@gmail.com</email></aff><author-notes><corresp id="c1-viruses-16-01815"><label>*</label>Correspondence: <email>danladinengakprecious@gmail.com</email>; Tel.: +23-48100681892</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1815</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The monkeypox outbreak has grown beyond the regions in which it was considered endemic. It has spread from central and west Africa to non-endemic regions like Europe, America, and other parts of the world. It has recently been classified as a public health emergency of international concern. This study evaluated the challenges faced globally and equitable access to monkeypox vaccines. Global competition has been observed in the race to obtain vaccines, with low- and middle-income countries being disadvantaged. Great inequity exists in the distribution of vaccines globally through advance purchase agreements, vaccine stockpiling, vaccine nationalism, the inequitable distribution of existing resources, and insufficient surveillance and reporting mechanisms. To address some of these challenges, there is a need for strengthening the global vaccine manufacturing capacity, targeting countries with elevated risk profiles and limited resources, strengthening surveillance systems, and addressing vaccine hesitancy.</p></abstract><kwd-group><kwd>monkeypox</kwd><kwd>challenges</kwd><kwd>equitable</kwd><kwd>vaccines</kwd><kwd>distribution</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01815"><title>1. Introduction</title><p>Caused by the MPOX virus (MPXV), monkeypox is a zoonotic double-stranded DNA virus belonging to the Orthopoxvirus genus within the Poxviridae family [<xref rid="B1-viruses-16-01815" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01815" ref-type="bibr">2</xref>]. This viral family also includes the variola virus, the causative agent of smallpox, a disease eradicated over forty-four years ago following widespread immunization efforts using the closely related vaccinia virus (VACV) [<xref rid="B3-viruses-16-01815" ref-type="bibr">3</xref>]. MPOX&#x02019;s first human case was in 1970 in the Democratic Republic of Congo (DRC). Since then, multiple cases have been reported across the tropical rainforest regions of western and central Africa [<xref rid="B4-viruses-16-01815" ref-type="bibr">4</xref>]. However, the MPOX virus (MPXV) outbreak has expanded beyond its traditional endemic areas of central and west Africa, spreading to multiple non-endemic countries across Europe, the Americas, and other parts of the world [<xref rid="B2-viruses-16-01815" ref-type="bibr">2</xref>,<xref rid="B4-viruses-16-01815" ref-type="bibr">4</xref>]. Five notable MPOX outbreaks have been documented, occurring in 1970, 1996&#x02013;1997, 2003, and 2018 [<xref rid="B3-viruses-16-01815" ref-type="bibr">3</xref>,<xref rid="B5-viruses-16-01815" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01815" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01815" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01815" ref-type="bibr">8</xref>]. Between January 2022 and August 2024, more than 120 countries documented MPOX cases, with over 100,000 confirmed cases in laboratories and more than 220 fatalities reported among these confirmed cases [<xref rid="B2-viruses-16-01815" ref-type="bibr">2</xref>,<xref rid="B9-viruses-16-01815" ref-type="bibr">9</xref>].</p><p>In the USA, 71 individuals were infected in 2003, with laboratory confirmation in 35 cases, due to contact between prairie dogs and African rodents. From 2018 to 2021, the UK reported seven MPOX cases, four linked to travel to regions where the disease is prevalent [<xref rid="B10-viruses-16-01815" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01815" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01815" ref-type="bibr">12</xref>]. In July 2021, two people returning from Nigeria were diagnosed with MPOX in Texas and Maryland, USA [<xref rid="B2-viruses-16-01815" ref-type="bibr">2</xref>,<xref rid="B13-viruses-16-01815" ref-type="bibr">13</xref>,<xref rid="B14-viruses-16-01815" ref-type="bibr">14</xref>]. The rapid global spread of the virus, primarily fueled by international travel and mobility, led to the World Health Organization (WHO) designating MPOX (MPXV) as a public health emergency of international concern (PHEIC) under the International Health Regulations [<xref rid="B15-viruses-16-01815" ref-type="bibr">15</xref>]. On August 14, 2024, the WHO Director-General officially declared the MPOX outbreak a public health emergency, highlighting the rapid spread of the disease, the growing number of cases globally, and the urgent need for coordinated international efforts to control its transmission [<xref rid="B16-viruses-16-01815" ref-type="bibr">16</xref>].</p><p>Over the years, vaccines have proven effective in infectious disease control and prevention, and MPOX is no exception [<xref rid="B17-viruses-16-01815" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01815" ref-type="bibr">18</xref>]. Given the close relationship between the two viruses, existing vaccines, such as the smallpox vaccine, have shown efficacy in preventing MPOX infections [<xref rid="B9-viruses-16-01815" ref-type="bibr">9</xref>,<xref rid="B18-viruses-16-01815" ref-type="bibr">18</xref>]. However, the global response to the MPOX outbreak has exposed deep-seated challenges in distribution and equitable vaccine access [<xref rid="B18-viruses-16-01815" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01815" ref-type="bibr">19</xref>]. Factors such as vaccine hoarding, a lack of manufacturing capacity in LMICs, logistical barriers, and intellectual property issues hinder equitable distribution [<xref rid="B17-viruses-16-01815" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01815" ref-type="bibr">18</xref>]. This research examines the global challenges in distributing and ensuring equitable access to MPOX vaccines. In doing so, it seeks to contribute to ongoing efforts to achieve equitable health outcomes in the global fight against emerging infectious diseases.</p></sec><sec id="sec2-viruses-16-01815"><title>2. Monkeypox Vaccines</title><p>Immunological reactions to a single Orthopox virus can recognize other Orthopox viruses and provide variable degrees of protection based on the similarity between the different Orthopox viruses. The viruses variola, vaccinia, and monkeypox (pox) are classified under the genus of Orthopox viruses. Because of shared antigens, vaccination can effectively prevent both variola and monkeypox. Recent research has demonstrated that the vaccinia vaccine, previously known for its efficacy in preventing smallpox, can also protect against the MPOX virus [<xref rid="B5-viruses-16-01815" ref-type="bibr">5</xref>,<xref rid="B20-viruses-16-01815" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01815" ref-type="bibr">21</xref>,<xref rid="B22-viruses-16-01815" ref-type="bibr">22</xref>,<xref rid="B23-viruses-16-01815" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01815" ref-type="bibr">24</xref>].</p><p>This immunological cross-reactivity has facilitated the development of several animal models of smallpox infection, which have been utilized to evaluate the effectiveness of vaccinations and antivirals [<xref rid="B25-viruses-16-01815" ref-type="bibr">25</xref>]. Two factors are primarily responsible for this cross-reactivity. Firstly, the Orthopox viruses exhibit a significant level of sequence similarity, particularly in immunologically essential proteins, resulting in a substantial number of common immune epitopes [<xref rid="B26-viruses-16-01815" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01815" ref-type="bibr">27</xref>]. The reaction includes a broad range of antibodies targeting a minimum of 24 membrane and structural proteins [<xref rid="B28-viruses-16-01815" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01815" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01815" ref-type="bibr">30</xref>]. Similarly, T cell responses detect epitopes in a wide range of viral proteins, with CD4 T cells showing a preference for recognizing structural proteins [<xref rid="B31-viruses-16-01815" ref-type="bibr">31</xref>], while CD8 T cells specifically target proteins that are encoded early in the viral life cycle, such as virulence factors [<xref rid="B32-viruses-16-01815" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01815" ref-type="bibr">33</xref>]. A neutralizing antibody was established to protect against smallpox (produced by the variola virus) in humans and against other Orthopox viruses in animal models. Though not essential for protection, T cells act by contributing to viral clearance [<xref rid="B34-viruses-16-01815" ref-type="bibr">34</xref>]. Some of the first evidence that vaccinia-specific immune responses can protect against MPOX came from investigations conducted in the 1980s. Three studies were conducted on chimpanzees, rhesus macaques, and cynomolgus macaques to determine the efficacy of smallpox vaccines against the MPOX virus using the Dryvax vaccine (first-generation smallpox vaccine). The result showed that almost all vaccinated animals were protected against the virus. The one exception to the above results was determined to have not responded to the vaccine. Although these studies were small, they suggested that smallpox vaccines offered some protection from the MPOX virus. This laid the groundwork for understanding the cross-protective immunity between smallpox and MPOX and has had a massive role in vaccine development and public health strategies [<xref rid="B35-viruses-16-01815" ref-type="bibr">35</xref>]. The relationship between the rise in MPOX cases following the end of smallpox vaccination and a growing population with limited immune exposure has been hypothesized and associated with a growing population with limited immune exposure. Due to concerns about bioterrorism and increasing outbreaks of the MPOX virus, the WHO has continued to license the smallpox vaccines [<xref rid="B35-viruses-16-01815" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01815" ref-type="bibr">36</xref>]. Smallpox vaccines are classified according to generation.</p><p>First-generation smallpox vaccines contained live vaccine viruses and were administered through bifurcated needles. Historically, patients with a characteristic pustule were protected against the virus. These vaccines, which include Dryvax<sup>&#x000ae;</sup>, APSV<sup>&#x000ae;</sup>, Lancy&#x02013;Vaxina<sup>&#x000ae;</sup>, and L-IVP<sup>&#x000ae;</sup>, were last produced in the early 1980s. Rare but potentially life-threatening complications, such as post-vaccinal encephalitis, progressive vaccinia, and myopericarditis, mainly occurred in immunocompromised patients [<xref rid="B35-viruses-16-01815" ref-type="bibr">35</xref>,<xref rid="B37-viruses-16-01815" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01815" ref-type="bibr">38</xref>]. Dryvax was developed by Wyeth Laboratories, consisting of the New York City Board of Health (NYCBH) strain of vaccinia and the Lister/Elstree and Ikeda vaccinia virus strains, which were lymph-derived and cultivated on the skin of animals [<xref rid="B36-viruses-16-01815" ref-type="bibr">36</xref>]. The routine use of this vaccine ended in the United States in 1972, the license for Dryvax was revoked in 2008, and the vaccine remains insufficient [<xref rid="B21-viruses-16-01815" ref-type="bibr">21</xref>]. The second-generation smallpox vaccines contained replication-competent viruses produced in a controlled laboratory setting. The focus was on eliciting a similar immune response to the first generation while curbing adverse side effects [<xref rid="B35-viruses-16-01815" ref-type="bibr">35</xref>,<xref rid="B37-viruses-16-01815" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01815" ref-type="bibr">38</xref>]. The third generation of smallpox vaccines concentrated on attenuated vaccine strains such as LC16m8, MVA, NYVAC, and dVVL to improve the safety profile [<xref rid="B37-viruses-16-01815" ref-type="bibr">37</xref>].</p><p>The United States (US) has authorized second- and third-generation smallpox vaccines for MPOX vaccination. Cell culture methods were utilized for their development to enhance the safety traits of these vaccines. In 2007, the US Food and Drug Administration licensed ACAM2000. It is generated from a clone of Dryvax. Originating from Emergent Bio Solutions, this vaccine is specifically designed for active vaccination against smallpox, excluding MPOX disease, in those with a high risk for smallpox virus infection [<xref rid="B39-viruses-16-01815" ref-type="bibr">39</xref>,<xref rid="B40-viruses-16-01815" ref-type="bibr">40</xref>]. While the efficacy of ACAM2000 in preventing MPOX has not been definitively shown, several studies have verified a certain level of immunogenicity. Additionally, one research study demonstrated protection against this virus by employing its first-generation progenitor, Dryvax [<xref rid="B41-viruses-16-01815" ref-type="bibr">41</xref>,<xref rid="B42-viruses-16-01815" ref-type="bibr">42</xref>]. Although the United States has a large stock of ACAM2000, this vaccine exhibits more adverse events and contraindications than the third generation [<xref rid="B39-viruses-16-01815" ref-type="bibr">39</xref>]. The adverse effects associated with this vaccine injection included pain and swelling at the injection site, fatigue, and muscular discomfort in about 50% of the recipients. Additionally, 20&#x02013;40% of the recipients experienced lymphadenopathy and headache, while around 20% had fever. About 20% of the recipients reported joint pain, backache, gastrointestinal pain, or nausea. More severe adverse effects encompassed widespread vaccinia, eczema vaccinatum, progressive vaccinia, post-vaccinal encephalopathy or encephalitis, and mortality. This vaccine was contraindicated for individuals with severely compromised immune systems, pregnant women or lactating mothers, those with cardiac disease or cardiac risk factors, individuals with active eczema, and infants under 12 months of age [<xref rid="B36-viruses-16-01815" ref-type="bibr">36</xref>,<xref rid="B43-viruses-16-01815" ref-type="bibr">43</xref>,<xref rid="B44-viruses-16-01815" ref-type="bibr">44</xref>,<xref rid="B45-viruses-16-01815" ref-type="bibr">45</xref>]. Additional vaccines based on the vaccinia virus were created by subjecting the virus to repeated passage in a primary cell culture or eggs to attenuate it [<xref rid="B36-viruses-16-01815" ref-type="bibr">36</xref>].</p><p>In 2019, the FDA approved JYNNEOS, a third-generation smallpox vaccine [<xref rid="B40-viruses-16-01815" ref-type="bibr">40</xref>]. It is a product of the Modified Vaccinia Ankara (MVA) attenuated strain, created through more than 500 serial passages of the vaccinia virus Ankara strain in chick embryo fibroblast cells. It is purified using tangential flow filtration and supplied as a frozen liquid suspension [<xref rid="B35-viruses-16-01815" ref-type="bibr">35</xref>,<xref rid="B42-viruses-16-01815" ref-type="bibr">42</xref>]. The vaccine is administered subcutaneously in two doses, 28 days apart, usually in the upper arm. JYNNEOS can also be administered intradermally, though this method is not recommended for individuals with weakened immune systems or a history of keloid scarring and is not preferred as the initial dose for post-exposure vaccination [<xref rid="B46-viruses-16-01815" ref-type="bibr">46</xref>]. After two doses, the immune response is comparable to that of ACAM2000 but with fewer side effects [<xref rid="B34-viruses-16-01815" ref-type="bibr">34</xref>,<xref rid="B47-viruses-16-01815" ref-type="bibr">47</xref>]. MVA-based vaccines do not produce the typical skin reaction. Still, common mild side effects include pain at the injection site (85% of recipients), redness, swelling, itching, and induration at the injection site (40&#x02013;60%), as well as fatigue, muscle aches, headaches (20&#x02013;40%), nausea (17%), and chills (10%). Fever is uncommon and observed in about 2% of recipients; cardiac events were reported in about 2%, with no cases of myopericarditis [<xref rid="B34-viruses-16-01815" ref-type="bibr">34</xref>]. The vaccine approval for the protection from smallpox in adults came from the European Medicines Agency (Amsterdam, The Netherlands) (EMA) in 2013 under the trade name IMVANEX and under the trade name IMVAMUNE from the Public Health Agency of Canada (PHAC) in the same year. In 2020, the PHAC expanded IMVAMUNE&#x02019;s use to include MPOX and other Orthopoxvirus infections, and in July 2022, the EMA similarly extended IMVANEX&#x02019;s use to cover monkeypox and vaccinia-related diseases [<xref rid="B48-viruses-16-01815" ref-type="bibr">48</xref>].</p><p>LC16m8 is another third-generation vaccine developed from the Lister strain used in first-generation vaccines. Through multiple tissue culture passages and selection for an attenuated phenotype, the LC16m8 strain was produced and lacked a full-length, functional B5 membrane protein [<xref rid="B34-viruses-16-01815" ref-type="bibr">34</xref>]. The vaccine is produced in cell culture using rabbit kidney cells and has been licensed since 1975 for active smallpox vaccination in Japan. In August 2022, Japan expanded the vaccine&#x02019;s use to include protection against MPOX. Due to their attenuated nature, these vaccines have a better safety profile and can be given to immunocompromised individuals. The effectiveness of these vaccines against MPOX is inferred from animal studies showing protection against the MPOX virus in non-human primates vaccinated with these vaccines, as well as clinical trials that have demonstrated their immunogenicity in humans [<xref rid="B36-viruses-16-01815" ref-type="bibr">36</xref>].</p><p>These vaccines can be used pre-exposure to prevent infection and illness or mitigate infection and disease post-exposure. Pre-exposure vaccination is recommended for individuals at the highest risk, with second- or third-generation vaccines providing the most effective protection. Post-exposure vaccination is ideally administered within four days of exposure to prevent infection. However, it can still be given up to 14 days after exposure to lessen the severity of the disease. Second- or third-generation vaccines are also preferred for post-exposure vaccination. In July 2022, authorities in Montreal, QC, Canada, administered at least 3000 doses [<xref rid="B34-viruses-16-01815" ref-type="bibr">34</xref>]. In all cases, healthcare professionals should know who may qualify for vaccination so they can consult national health authorities about accessing vaccines from national stockpiles. Smallpox vaccines are not available commercially or privately.</p></sec><sec id="sec3-viruses-16-01815"><title>3. Challenges in Global Distribution of Monkeypox Vaccines</title><p>The World Health Organization (WHO) has drawn attention to global competition for Mpox vaccines, with 35 countries vying for access to the 16.4 million currently available doses [<xref rid="B49-viruses-16-01815" ref-type="bibr">49</xref>]. There is a growing concern that low-income countries may encounter challenges securing the vaccine [<xref rid="B50-viruses-16-01815" ref-type="bibr">50</xref>]. Most notably, many African countries where Mpox has been prevalent for decades are yet to receive a single dose of the vaccine. Wealthier nations have obtained most of the available doses, limiting options for other affected countries, particularly those in Africa [<xref rid="B50-viruses-16-01815" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01815" ref-type="bibr">51</xref>].</p><p>AIDS, COVID-19, and the current monkeypox outbreak are evidence of inequities in global health strategy. It can be observed that global health strategies for disease burden control are only put in place when the Global North (developed countries) is affected [<xref rid="B3-viruses-16-01815" ref-type="bibr">3</xref>]. The concentration of global vaccine production in the Global North, with numerous vaccine production facilities in the United States, Japan, and Europe, has led to a reliance on vaccine supply from these regions. This reliance creates significant inequity in global vaccine coverage and insufficient domestic production, particularly in low- and middle-income nations [<xref rid="B52-viruses-16-01815" ref-type="bibr">52</xref>]. Despite the establishment of vaccine production facilities by foreign pharmaceutical industries across Africa [<xref rid="B53-viruses-16-01815" ref-type="bibr">53</xref>], they still produce less than 1% of all vaccines used on the continent [<xref rid="B54-viruses-16-01815" ref-type="bibr">54</xref>].</p><p>Additional challenges, such as the lack of qualified personnel, specialized vaccine development, and manufacturing infrastructure, inadequate training, ineffective awareness campaigns, and difficulties collecting and processing critical immunization data, further complicate the situation [<xref rid="B50-viruses-16-01815" ref-type="bibr">50</xref>].</p><p>Furthermore, challenges such as an unstable electricity supply and inadequate cold chain facilities could significantly impede comprehensive vaccine manufacturing in Africa [<xref rid="B50-viruses-16-01815" ref-type="bibr">50</xref>].</p></sec><sec id="sec4-viruses-16-01815"><title>4. Barriers to Equitable Access to Monkeypox Vaccines</title><p><italic toggle="yes">Advance Purchase Agreements:</italic> High-income countries have leveraged advance purchase agreements (APAs) to secure priority access to newly produced vaccines. These agreements allow wealthier nations to stockpile vaccines, often at the expense of countries that may be more affected by monkeypox. This practice not only limits the availability of vaccines for lower-income nations but also reinforces inequities, as those countries cannot compete financially in the vaccine market. A more equitable approach would involve manufacturers setting aside a portion of their vaccine supply for global distribution, ensuring that all countries have access regardless of their economic status [<xref rid="B55-viruses-16-01815" ref-type="bibr">55</xref>].</p><p><italic toggle="yes">Vaccine Stockpiling Reluctance:</italic> Nations with large stockpiles of vaccines are often hesitant to share these resources. This reluctance stems from concerns about maintaining sufficient supplies for their populations amid outbreaks. However, this hoarding behavior exacerbates global disparities in vaccine access, particularly affecting historically endemic countries that experience the highest case fatality rates. To address this issue, countries should commit to contributing a portion of their stockpiled vaccines to an international distribution network, aligning their actions with global health commitments, and fostering collective security against outbreaks [<xref rid="B55-viruses-16-01815" ref-type="bibr">55</xref>].</p><p><italic toggle="yes">Lack of Organized Mechanisms for Low-Income Countries:</italic> Many low-income nations lack the infrastructure and financial means to procure vaccines independently, relying instead on international aid and charity. This dependency can lead to inconsistent access and delays in vaccination efforts, ultimately allowing the disease to spread unchecked. Establishing a coordinated global procurement and distribution system could help bridge this gap. Like the successful Revolving Fund for Access to Vaccines in the Americas, such a system would provide a structured approach for low-income countries to secure necessary vaccines, ensuring they are not left behind during public health emergencies [<xref rid="B55-viruses-16-01815" ref-type="bibr">55</xref>].</p><p><italic toggle="yes">Vaccine Nationalism:</italic> During health crises, many countries prioritize securing vaccines for their populations, a practice often called vaccine nationalism. This trend was evident during past outbreaks, such as those of H1N1 and COVID-19, where wealthier nations quickly acquired the majority of available doses, leaving low-income countries with limited access. The current landscape for monkeypox is no different, as high-income countries have disproportionately secured vaccine supplies, creating a significant gap in availability for those most affected. To combat this, international frameworks and agreements are needed to promote fair distribution practices and discourage hoarding [<xref rid="B55-viruses-16-01815" ref-type="bibr">55</xref>,<xref rid="B56-viruses-16-01815" ref-type="bibr">56</xref>].</p><p><italic toggle="yes">Inequitable Distribution of Existing Resources:</italic> Even when vaccines are available, their distribution is often inequitable. Many countries with a high monkeypox prevalence receive little to no doses, while nations with minimal cases secure large quantities. This disconnect between the disease burden and vaccine access is unjust and highlights a critical need for allocation strategies prioritizing regions most in need. Developing criteria based on case severity and potential risk factors can help guide equitable distribution [<xref rid="B55-viruses-16-01815" ref-type="bibr">55</xref>].</p><p><italic toggle="yes">Insufficient Surveillance and Reporting Mechanisms:</italic> Countries needing more robust health surveillance systems often need help accurately documenting monkeypox cases. This limitation can lead to underreporting, resulting in these countries receiving fewer vaccines due to perceived lower needs. To address this, international support is crucial for building the surveillance capacity in vulnerable nations. Enhanced data collection and reporting will improve vaccine allocation decisions and help contain future outbreaks effectively [<xref rid="B55-viruses-16-01815" ref-type="bibr">55</xref>].</p></sec><sec id="sec5-viruses-16-01815"><title>5. Strategies to Improve Global Distribution and Access</title><p>The global distribution of the monkeypox vaccine has faced many challenges, especially in ensuring equitable distribution and access for vulnerable populations. It can be improved through (1) enhancing global health policies; (2) establishing a new public health structure [<xref rid="B57-viruses-16-01815" ref-type="bibr">57</xref>]; (3) global health financing [<xref rid="B58-viruses-16-01815" ref-type="bibr">58</xref>]; (4) addressing pharmaceutical monopolies [<xref rid="B57-viruses-16-01815" ref-type="bibr">57</xref>]; (5) price transparency [<xref rid="B59-viruses-16-01815" ref-type="bibr">59</xref>]; (6) enhancing vaccine confidence and uptake; (7) utilizing social media for communication [<xref rid="B59-viruses-16-01815" ref-type="bibr">59</xref>]; (8) implementing ring vaccination strategies [<xref rid="B60-viruses-16-01815" ref-type="bibr">60</xref>]; and (9) international cooperation and solidarity [<xref rid="B61-viruses-16-01815" ref-type="bibr">61</xref>].</p></sec><sec id="sec6-viruses-16-01815"><title>6. Recommendations</title><sec id="sec6dot1-viruses-16-01815"><title>6.1. Strengthening Global Vaccine Manufacturing Capacity</title><p>Significant disparities in the fair access to necessary medical countermeasures, such as vaccines, were brought to light by the COVID-19 pandemic. The manufacturing capacity for pandemic vaccines is concentrated in too few countries. Eight of every ten vaccine doses produced have gone to high-income countries [<xref rid="B61-viruses-16-01815" ref-type="bibr">61</xref>]. Expanding the manufacturing capacity across different regions is crucial to overcoming supply constraints, particularly in low- and middle-income countries (LMICs). This could involve transferring technology to these regions, fostering partnerships between pharmaceutical companies and local producers, and encouraging cooperation between players from the public sector, business sector, academic institutions, and civil society.</p></sec><sec id="sec6dot2-viruses-16-01815"><title>6.2. Targeting Countries with Elevated Risk Profiles and Limited Access to Resources</title><p>Nigeria, Ghana, and Cameroon have recorded about 15% of global monkeypox fatalities since 2022 but have fewer than 1% of the total cases worldwide [<xref rid="B4-viruses-16-01815" ref-type="bibr">4</xref>]. Countries should be prioritized based on ethical principles. This prioritization could specify the order in which countries receive required doses or how large a share they receive from a given tranche. Under either method, historically endemic countries should receive the highest priority for monkeypox vaccines. After that, the priority should be determined using countries&#x02019; projected cases and severity of outcomes [<xref rid="B62-viruses-16-01815" ref-type="bibr">62</xref>]. Vaccine distribution should prioritize regions experiencing the highest monkeypox incidence and populations at higher risk.</p></sec><sec id="sec6dot3-viruses-16-01815"><title>6.3. Overcoming Vaccine Nationalism Through Platforms Like COVAX</title><p>Platforms such as COVAX (COVID-19 Vaccines Global Access) could be adapted to include monkeypox vaccines, ensuring a more coordinated global response. Establishing an international task force similar to the ACT Accelerator (Access to COVID-19 Tools), used during COVID-19 could facilitate the distribution of monkeypox vaccines to the most vulnerable populations. COVAX was designed as an end-to-end coordination mechanism encompassing research and development and manufacturing, policy guidance, vaccine portfolio development, regulatory systems, supply allocation and country readiness assessments, transport logistics, vaccine storage and administration, and the monitoring of country coverage and absorption rates. It significantly alleviated the suffering caused by COVID-19 in the Global South (low-income countries). Today, the initiative has supplied 74% of all COVID-19 vaccine doses provided to low-income countries (LICs) during the pandemic. A total of 52 of the 92 AMC-eligible economies relied on COVAX for over half of their COVID-19 vaccine supply [<xref rid="B63-viruses-16-01815" ref-type="bibr">63</xref>].</p></sec><sec id="sec6dot4-viruses-16-01815"><title>6.4. Strengthening Health Surveillance Systems</title><p>A significant contributor to vaccine access inequities, especially in low- and middle-income countries, is the underreporting of Mpox cases, especially in the central and west African regions [<xref rid="B57-viruses-16-01815" ref-type="bibr">57</xref>]. This is mainly attributable to the weak health surveillance systems in rural areas, which prevent the early detection of cases, leading to the underreporting of cases. Due to this, the disease&#x02019;s hotspots may not be readily identified early, consequently preventing vaccines from being allocated to such areas. To address this issue, we recommend strengthening health surveillance systems in these regions by providing early warning systems incorporating robust data collection and sharing mechanisms. This will help prompt the detection and identification of cases in this region. In addition, assisting financially and technically to the end of developing disease monitoring and reporting systems, especially in low- and middle-income countries, will help improve vaccine access and equity [<xref rid="B57-viruses-16-01815" ref-type="bibr">57</xref>].</p></sec><sec id="sec6dot5-viruses-16-01815"><title>6.5. Addressing Vaccine Hesitancy</title><p>A key challenge in the equitable distribution of Mpox vaccines is the unwillingness of people to receive these vaccines despite their availability. This is especially common in the Global South due to a need for more awareness, misinformation, or both [<xref rid="B50-viruses-16-01815" ref-type="bibr">50</xref>]. The addressing of vaccine hesitancy by healthcare workers, community leaders, and local influencers is paramount. This can be achieved via well-planned public health campaigns and community engagement aimed at adequately informing people about and sensitizing people to the importance of vaccines, debunking myths about vaccines, and encouraging at-risk populations to get vaccinated. This would increase vaccination and the acceptance of vaccines [<xref rid="B64-viruses-16-01815" ref-type="bibr">64</xref>,<xref rid="B65-viruses-16-01815" ref-type="bibr">65</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec7-viruses-16-01815"><title>7. Conclusions</title><p>As the world continues to grapple with the Mpox epidemic, with some countries being more significantly affected than others, there is an urgent need for a collaborative and progressive approach towards ensuring that countermeasures are not only provided but also fairly and equitably distributed to affected countries. Overcoming the challenges facing global distribution and equitable access to the MPox vaccine through measures such as strengthening the global vaccine manufacturing capacity, overcoming vaccine nationalism through platforms like COVAX, and addressing vaccine hesitancy are crucial steps in the fight against the Mpox epidemic. The development of international research and development centers, as well as vaccine distribution centers, can improve vaccine availability, reduce scarcity, and address the need for vaccine nationalism or hoarding. A global perspective policy on the equitable distribution of vaccines not just for Mpox but for other diseases is crucial.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, N.P.D. and P.A.; methodology, N.P.D. and P.A; resources, N.P.D., P.A., P.O., S.E., O.O., D.O., O.S.A., O.A.A., K.O., A.I.A. and A.P.; writing&#x02014;original draft preparation, N.P.D., P.A., P.O., S.E., O.O., D.O., O.S.A., O.A.A., K.O., A.I.A. and A.P.; writing&#x02014;review and editing, N.P.D., P.A., P.O., S.E. and O.O.; supervision, N.P.D.; project administration, N.P.D. and O.O.; All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01815"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Shahed-AI-Mahmud</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Tan</surname><given-names>H.</given-names></name>
<name><surname>Joyce</surname><given-names>R.</given-names></name>
</person-group><article-title>An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>4468</fpage><lpage>4490</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00069</pub-id><pub-id pub-id-type="pmid">36961984</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01815"><label>2.</label><element-citation publication-type="webpage"><article-title>Mpox</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/mpox" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/mpox</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-01">(accessed on 1 October 2024)</date-in-citation></element-citation></ref><ref id="B3-viruses-16-01815"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitj&#x000e0;</surname><given-names>O.</given-names></name>
<name><surname>Alemany</surname><given-names>A.</given-names></name>
<name><surname>Marks</surname><given-names>M.</given-names></name>
<name><surname>Mora</surname><given-names>J.I.L.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Aldama</surname><given-names>J.C.</given-names></name>
<name><surname>Silva</surname><given-names>M.S.T.</given-names></name>
<name><surname>Herrera</surname><given-names>E.A.C.</given-names></name>
<name><surname>Crabtree-Ramirez</surname><given-names>B.</given-names></name>
<name><surname>Blanco</surname><given-names>J.L.</given-names></name>
<name><surname>Girometti</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Mpox in people with advanced HIV infection: A global case series</article-title><source>Lancet</source><year>2023</year><volume>401</volume><fpage>939</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)00273-8</pub-id><pub-id pub-id-type="pmid">36828001</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01815"><label>4.</label><element-citation publication-type="gov"><article-title>Monkeypox Outbreak Global Map: Cases</article-title><comment>Available online: <ext-link xlink:href="https://stacks.cdc.gov/view/cdc/123104" ext-link-type="uri">https://stacks.cdc.gov/view/cdc/123104</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B5-viruses-16-01815"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bunge</surname><given-names>E.M.</given-names></name>
<name><surname>Hoet</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Lienert</surname><given-names>F.</given-names></name>
<name><surname>Weidenthaler</surname><given-names>H.</given-names></name>
<name><surname>Baer</surname><given-names>L.R.</given-names></name>
<name><surname>Steffen</surname><given-names>R.</given-names></name>
</person-group><article-title>The changing epidemiology of human monkeypox&#x02014;A potential threat? A systematic review</article-title><source>PLoS Neglect. Trop. Dis.</source><year>2022</year><volume>16</volume><elocation-id>e0010141</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0010141</pub-id><pub-id pub-id-type="pmid">35148313</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01815"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alakunle</surname><given-names>E.F.</given-names></name>
<name><surname>Okeke</surname><given-names>M.I.</given-names></name>
</person-group><article-title>Monkeypox virus: A neglected zoonotic pathogen spreads globally</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>507</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00776-z</pub-id><pub-id pub-id-type="pmid">35859005</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01815"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meseko</surname><given-names>C.</given-names></name>
<name><surname>Adedeji</surname><given-names>A.</given-names></name>
<name><surname>Shittu</surname><given-names>I.</given-names></name>
<name><surname>Obishakin</surname><given-names>E.</given-names></name>
<name><surname>Nanven</surname><given-names>M.</given-names></name>
<name><surname>Suleiman</surname><given-names>L.</given-names></name>
<name><surname>Okomah</surname><given-names>D.</given-names></name>
<name><surname>Tyakaray</surname><given-names>V.</given-names></name>
<name><surname>Kolade</surname><given-names>D.</given-names></name>
<name><surname>Yinka-Ogunleye</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Orthopoxvirus Infections in Rodents, Nigeria, 2018&#x02013;2019</article-title><source>Emerg. Infect. Dis.</source><year>2023</year><volume>29</volume><fpage>433</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.3201/eid2902.221411</pub-id><pub-id pub-id-type="pmid">36692495</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01815"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Precious</surname><given-names>N.D.B.</given-names></name>
<name><surname>Agboola</surname><given-names>P.B.</given-names></name>
<name><surname>Oluwatimilehin</surname><given-names>O.B.</given-names></name>
<name><surname>Olakunle</surname><given-names>O.K.B.</given-names></name>
<name><surname>Olaniyi</surname><given-names>P.B.</given-names></name>
<name><surname>Adiatu</surname><given-names>A.I.B.</given-names></name>
<name><surname>Olusogo</surname><given-names>A.P.B.</given-names></name>
<name><surname>Obiwulu</surname><given-names>D.J.B.</given-names></name>
<name><surname>Adeola</surname><given-names>O.A.B.</given-names></name>
<name><surname>Ebubechukwu</surname><given-names>E.S.B.</given-names></name>
<etal/>
</person-group><article-title>Re-emergence of monkeypox virus outbreak in Nigeria: Epidemic preparedness and response (Review-Commentary)</article-title><source>Ann. Med. Surg.</source><year>2023</year><volume>85</volume><fpage>3990</fpage><lpage>3996</lpage><pub-id pub-id-type="doi">10.1097/MS9.0000000000001069</pub-id></element-citation></ref><ref id="B9-viruses-16-01815"><label>9.</label><element-citation publication-type="gov"><article-title>Mpox 2022 Outbreak Cases and Data</article-title><comment>Available online: <ext-link xlink:href="https://stacks.cdc.gov/view/cdc/131079" ext-link-type="uri">https://stacks.cdc.gov/view/cdc/131079</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B10-viruses-16-01815"><label>10.</label><element-citation publication-type="gov"><article-title>Update: Multistate Outbreak of Monkeypox&#x02014;Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin</article-title><year>2003</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a5.htm" ext-link-type="uri">https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a5.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B11-viruses-16-01815"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fleischauer</surname><given-names>A.T.</given-names></name>
<name><surname>Kile</surname><given-names>J.C.</given-names></name>
<name><surname>Davidson</surname><given-names>M.</given-names></name>
<name><surname>Fischer</surname><given-names>M.</given-names></name>
<name><surname>Karem</surname><given-names>K.L.</given-names></name>
<name><surname>Teclaw</surname><given-names>R.</given-names></name>
<name><surname>Messersmith</surname><given-names>H.</given-names></name>
<name><surname>Pontones</surname><given-names>P.</given-names></name>
<name><surname>Beard</surname><given-names>B.A.</given-names></name>
<name><surname>Braden</surname><given-names>Z.H.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of Human-to-Human Transmission of Monkeypox from Infected Patients to Health Care Workers</article-title><source>Clin. Infect. Dis.</source><year>2005</year><volume>40</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1086/427805</pub-id><pub-id pub-id-type="pmid">15714414</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01815"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kava</surname><given-names>C.M.</given-names></name>
<name><surname>Rohraff</surname><given-names>D.M.</given-names></name>
<name><surname>Wallace</surname><given-names>B.</given-names></name>
<name><surname>Mendoza-Alonzo</surname><given-names>J.L.</given-names></name>
<name><surname>Currie</surname><given-names>D.W.</given-names></name>
<name><surname>Munsey</surname><given-names>A.E.</given-names></name>
<name><surname>Roth</surname><given-names>N.M.</given-names></name>
<name><surname>Bryant-Genevier</surname><given-names>J.</given-names></name>
<name><surname>Kennedy</surname><given-names>J.L.</given-names></name>
<name><surname>Weller</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title>Epidemiologic Features of the Monkeypox Outbreak and the Public Health Response&#x02014;United States, May 17&#x02013;October 6, 2022</article-title><source>MMWR-Morb. Mortal. Wkly. Rep.</source><year>2022</year><volume>71</volume><fpage>1449</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7145a4</pub-id><pub-id pub-id-type="pmid">36355615</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01815"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adler</surname><given-names>H.</given-names></name>
<name><surname>Gould</surname><given-names>S.</given-names></name>
<name><surname>Hine</surname><given-names>P.</given-names></name>
<name><surname>Snell</surname><given-names>L.B.</given-names></name>
<name><surname>Wong</surname><given-names>W.</given-names></name>
<name><surname>Houlihan</surname><given-names>C.F.</given-names></name>
<name><surname>Osborne</surname><given-names>J.C.</given-names></name>
<name><surname>Rampling</surname><given-names>T.</given-names></name>
<name><surname>Beadsworth</surname><given-names>M.B.</given-names></name>
<name><surname>Duncan</surname><given-names>C.J.</given-names></name>
<etal/>
</person-group><article-title>Clinical features and management of human monkeypox: A retrospective observational study in the UK</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>1153</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00228-6</pub-id><pub-id pub-id-type="pmid">35623380</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01815"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaughan</surname><given-names>A.</given-names></name>
<name><surname>Aarons</surname><given-names>E.</given-names></name>
<name><surname>Astbury</surname><given-names>J.</given-names></name>
<name><surname>Brooks</surname><given-names>T.</given-names></name>
<name><surname>Chand</surname><given-names>M.</given-names></name>
<name><surname>Flegg</surname><given-names>P.</given-names></name>
<name><surname>Hardman</surname><given-names>A.</given-names></name>
<name><surname>Harper</surname><given-names>N.</given-names></name>
<name><surname>Jarvis</surname><given-names>R.</given-names></name>
<name><surname>Mawdsley</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>782</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.3201/eid2604.191164</pub-id><pub-id pub-id-type="pmid">32023204</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01815"><label>15.</label><element-citation publication-type="webpage"><article-title>WHO Director-General&#x02019;s Statement at the Press Conference Following IHR Emergency Committee Regarding the Multi-Country Outbreak of Monkeypox&#x02014;23 July 2022</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022" ext-link-type="uri">https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B16-viruses-16-01815"><label>16.</label><element-citation publication-type="webpage"><article-title>WHO Director-General Declares Mpox Outbreak a Public Health Emergency of International Concern</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern" ext-link-type="uri">https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B17-viruses-16-01815"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greenwood</surname><given-names>B.</given-names></name>
</person-group><article-title>The contribution of vaccination to global health: Past, present and future</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2014</year><volume>369</volume><elocation-id>20130433</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmid">24821919</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01815"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watarkar</surname><given-names>S.M.</given-names></name>
<name><surname>Upadhyay</surname><given-names>P.</given-names></name>
<name><surname>Ghosh</surname><given-names>S.M.</given-names></name>
<name><surname>Godbole</surname><given-names>A.A.M.</given-names></name>
<name><surname>Kishori</surname><given-names>S.K.M.</given-names></name>
<name><surname>Mohanty</surname><given-names>A.</given-names></name>
<name><surname>Padhi</surname><given-names>B.K.</given-names></name>
<name><surname>Sah</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Vaccines for monkeypox disease and challenges in its production and distribution: A lesson from COVID-19 pandemic</article-title><source>Int. J. Surg.</source><year>2023</year><volume>109</volume><fpage>536</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1097/JS9.0000000000000016</pub-id><pub-id pub-id-type="pmid">36906772</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01815"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirani</surname><given-names>R.</given-names></name>
<name><surname>Noruzi</surname><given-names>K.</given-names></name>
<name><surname>Iqbal</surname><given-names>A.</given-names></name>
<name><surname>Hussaini</surname><given-names>A.S.</given-names></name>
<name><surname>Khan</surname><given-names>R.A.</given-names></name>
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Etienne</surname><given-names>M.</given-names></name>
<name><surname>Tiwari</surname><given-names>R.K.</given-names></name>
</person-group><article-title>A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>2713</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11112713</pub-id><pub-id pub-id-type="pmid">38004725</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01815"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>J.</given-names></name>
<name><surname>Lipsitch</surname><given-names>M.</given-names></name>
<name><surname>Almond</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Vaccine production, distribution, access, and uptake</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>428</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60478-9</pub-id><pub-id pub-id-type="pmid">21664680</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01815"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rimoin</surname><given-names>A.W.</given-names></name>
<name><surname>Mulembakani</surname><given-names>P.M.</given-names></name>
<name><surname>Johnston</surname><given-names>S.C.</given-names></name>
<name><surname>Smith</surname><given-names>J.O.L.</given-names></name>
<name><surname>Kisalu</surname><given-names>N.K.</given-names></name>
<name><surname>Kinkela</surname><given-names>T.L.</given-names></name>
<name><surname>Blumberg</surname><given-names>S.</given-names></name>
<name><surname>Thomassen</surname><given-names>H.A.</given-names></name>
<name><surname>Pike</surname><given-names>B.L.</given-names></name>
<name><surname>Fair</surname><given-names>J.N.</given-names></name>
<etal/>
</person-group><article-title>Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>16262</fpage><lpage>16267</lpage><pub-id pub-id-type="doi">10.1073/pnas.1005769107</pub-id><pub-id pub-id-type="pmid">20805472</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01815"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>P.-Y.</given-names></name>
<name><surname>Ajisegiri</surname><given-names>W.S.</given-names></name>
<name><surname>Costantino</surname><given-names>V.</given-names></name>
<name><surname>Chughtai</surname><given-names>A.A.</given-names></name>
<name><surname>MacIntyre</surname><given-names>C.R.</given-names></name>
</person-group><article-title>Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017&#x02013;2020</article-title><source>Emerg. Infect. Dis.</source><year>2021</year><volume>27</volume><fpage>1007</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.3201/eid2704.203569</pub-id><pub-id pub-id-type="pmid">33756100</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01815"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>Y.-H.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Cao</surname><given-names>J.-L.</given-names></name>
<name><surname>Hou</surname><given-names>W.-S.</given-names></name>
<name><surname>Wang</surname><given-names>A.-Q.</given-names></name>
<name><surname>Jin</surname><given-names>C.-H.</given-names></name>
</person-group><article-title>Monkeypox: An outbreak of a rare viral disease</article-title><source>J. Microbiol. Immunol. Infect.</source><year>2023</year><volume>57</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2023.12.006</pub-id><pub-id pub-id-type="pmid">38177001</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01815"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>M.G.</given-names></name>
<name><surname>Damon</surname><given-names>I.K.</given-names></name>
</person-group><article-title>Outbreaks of human monkeypox after cessation of smallpox vaccination</article-title><source>Trends Microbiol.</source><year>2012</year><volume>20</volume><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2011.12.001</pub-id><pub-id pub-id-type="pmid">22239910</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01815"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Townsend</surname><given-names>M.B.</given-names></name>
<name><surname>Keckler</surname><given-names>M.S.</given-names></name>
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Davies</surname><given-names>D.H.</given-names></name>
<name><surname>Felgner</surname><given-names>P.</given-names></name>
<name><surname>Damon</surname><given-names>I.K.</given-names></name>
<name><surname>Karem</surname><given-names>K.L.</given-names></name>
</person-group><article-title>Humoral Immunity to Smallpox Vaccines and Monkeypox Virus Challenge: Proteomic Assessment and Clinical Correlations</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>900</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1128/JVI.02089-12</pub-id><pub-id pub-id-type="pmid">23135728</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01815"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manes</surname><given-names>N.P.</given-names></name>
<name><surname>Estep</surname><given-names>R.D.</given-names></name>
<name><surname>Mottaz</surname><given-names>H.M.</given-names></name>
<name><surname>Moore</surname><given-names>R.J.</given-names></name>
<name><surname>Clauss</surname><given-names>T.R.W.</given-names></name>
<name><surname>Monroe</surname><given-names>M.E.</given-names></name>
<name><surname>Du</surname><given-names>X.</given-names></name>
<name><surname>Adkins</surname><given-names>J.N.</given-names></name>
<name><surname>Wong</surname><given-names>S.W.</given-names></name>
<name><surname>Smith</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Comparative Proteomics of Human Monkeypox and Vaccinia Intracellular Mature and Extracellular Enveloped Virions</article-title><source>J. Proteome Res.</source><year>2008</year><volume>7</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1021/pr070432+</pub-id><pub-id pub-id-type="pmid">18205298</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01815"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Molero-Abraham</surname><given-names>M.</given-names></name>
<name><surname>Glutting</surname><given-names>J.-P.</given-names></name>
<name><surname>Flower</surname><given-names>D.R.</given-names></name>
<name><surname>Lafuente</surname><given-names>E.M.</given-names></name>
<name><surname>Reche</surname><given-names>P.A.</given-names></name>
</person-group><article-title>EPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic Orthopoxviruses</article-title><source>J. Immunol. Res.</source><year>2015</year><volume>2015</volume><fpage>738020</fpage><pub-id pub-id-type="doi">10.1155/2015/738020</pub-id><pub-id pub-id-type="pmid">26605344</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01815"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benhnia</surname><given-names>M.R.-E.</given-names></name>
<name><surname>McCausland</surname><given-names>M.M.</given-names></name>
<name><surname>Su</surname><given-names>H.-P.</given-names></name>
<name><surname>Singh</surname><given-names>K.</given-names></name>
<name><surname>Hoffmann</surname><given-names>J.</given-names></name>
<name><surname>Davies</surname><given-names>D.H.</given-names></name>
<name><surname>Felgner</surname><given-names>P.L.</given-names></name>
<name><surname>Head</surname><given-names>S.</given-names></name>
<name><surname>Sette</surname><given-names>A.</given-names></name>
<name><surname>Garboczi</surname><given-names>D.N.</given-names></name>
<etal/>
</person-group><article-title>Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>3751</fpage><lpage>3768</lpage><pub-id pub-id-type="doi">10.1128/JVI.02244-07</pub-id><pub-id pub-id-type="pmid">18234801</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01815"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>D.H.</given-names></name>
<name><surname>Molina</surname><given-names>D.M.</given-names></name>
<name><surname>Wrammert</surname><given-names>J.</given-names></name>
<name><surname>Miller</surname><given-names>J.</given-names></name>
<name><surname>Hirst</surname><given-names>S.</given-names></name>
<name><surname>Mu</surname><given-names>Y.</given-names></name>
<name><surname>Pablo</surname><given-names>J.</given-names></name>
<name><surname>Unal</surname><given-names>B.</given-names></name>
<name><surname>Nakajima-Sasaki</surname><given-names>R.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Proteome-wide analysis of the serological response to vaccinia and smallpox</article-title><source>Proteomics</source><year>2007</year><volume>7</volume><fpage>1678</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1002/pmic.200600926</pub-id><pub-id pub-id-type="pmid">17443847</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01815"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>R.B.</given-names></name>
<name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name>
<name><surname>Haralambieva</surname><given-names>I.H.</given-names></name>
<name><surname>Grill</surname><given-names>D.E.</given-names></name>
<name><surname>Poland</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Proteomic assessment of humoral immune responses in smallpox vaccine recipients</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>789</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.12.033</pub-id><pub-id pub-id-type="pmid">34952760</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01815"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jing</surname><given-names>L.</given-names></name>
<name><surname>Davies</surname><given-names>D.H.</given-names></name>
<name><surname>Chong</surname><given-names>T.M.</given-names></name>
<name><surname>Chun</surname><given-names>S.</given-names></name>
<name><surname>McClurkan</surname><given-names>C.L.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Story</surname><given-names>B.T.</given-names></name>
<name><surname>Molina</surname><given-names>D.M.</given-names></name>
<name><surname>Hirst</surname><given-names>S.</given-names></name>
<name><surname>Felgner</surname><given-names>P.L.</given-names></name>
<etal/>
</person-group><article-title>An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>7120</fpage><lpage>7134</lpage><pub-id pub-id-type="doi">10.1128/JVI.00453-08</pub-id><pub-id pub-id-type="pmid">18480455</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01815"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terajima</surname><given-names>M.</given-names></name>
<name><surname>Orphin</surname><given-names>L.</given-names></name>
<name><surname>Leporati</surname><given-names>A.M.</given-names></name>
<name><surname>Pazoles</surname><given-names>P.</given-names></name>
<name><surname>Cruz</surname><given-names>J.</given-names></name>
<name><surname>Rothman</surname><given-names>A.L.</given-names></name>
<name><surname>Ennis</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Vaccinia virus-specific CD8+ T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans</article-title><source>Hum. Immunol.</source><year>2008</year><volume>69</volume><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2008.09.009</pub-id><pub-id pub-id-type="pmid">18955096</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01815"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jing</surname><given-names>L.</given-names></name>
<name><surname>Chong</surname><given-names>T.M.</given-names></name>
<name><surname>McClurkan</surname><given-names>C.L.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Story</surname><given-names>B.T.</given-names></name>
<name><surname>Koelle</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Diversity in the Acute CD8 T Cell Response to Vaccinia Virus in Humans</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>7550</fpage><lpage>7559</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.11.7550</pub-id><pub-id pub-id-type="pmid">16301664</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01815"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poland</surname><given-names>G.A.</given-names></name>
<name><surname>Kennedy</surname><given-names>R.B.</given-names></name>
<name><surname>Tosh</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Prevention of monkeypox with vaccines: A rapid review</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>e349</fpage><lpage>e358</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00574-6</pub-id><pub-id pub-id-type="pmid">36116460</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01815"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>R.B.</given-names></name>
<name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name>
<name><surname>Jacobson</surname><given-names>R.M.</given-names></name>
<name><surname>Poland</surname><given-names>G.A.</given-names></name>
</person-group><article-title>The immunology of smallpox vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2009</year><volume>21</volume><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.04.004</pub-id><pub-id pub-id-type="pmid">19524427</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01815"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gruber</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Current status of monkeypox vaccines</article-title><source>Npj Vaccines</source><year>2022</year><volume>7</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00527-4</pub-id><pub-id pub-id-type="pmid">35977979</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01815"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parrino</surname><given-names>J.</given-names></name>
<name><surname>Graham</surname><given-names>B.</given-names></name>
</person-group><article-title>Smallpox vaccines: Past, present, and future</article-title><source>J. Allergy Clin. Immunol.</source><year>2006</year><volume>118</volume><fpage>1320</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2006.09.037</pub-id><pub-id pub-id-type="pmid">17157663</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01815"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jandrasits</surname><given-names>D.</given-names></name>
<name><surname>Z&#x000fc;st</surname><given-names>R.</given-names></name>
<name><surname>Siegrist</surname><given-names>D.</given-names></name>
<name><surname>Engler</surname><given-names>O.B.</given-names></name>
<name><surname>Weber</surname><given-names>B.</given-names></name>
<name><surname>Schmidt</surname><given-names>K.M.</given-names></name>
<name><surname>Jonsdottir</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Third-generation smallpox vaccines induce low-level cross-protecting neutralizing antibodies against Monkeypox virus in laboratory workers</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e31490</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e31490</pub-id><pub-id pub-id-type="pmid">38826712</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01815"><label>39.</label><element-citation publication-type="gov"><article-title>Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States|Mpox|CDC</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/mpox/hcp/vaccine-considerations/vaccination-overview.html?CDC_AAref_Val=https://www.cdc.gov/poxvirus/MPOX/interim-considerations/overview.html" ext-link-type="uri">https://www.cdc.gov/mpox/hcp/vaccine-considerations/vaccination-overview.html?CDC_AAref_Val=https://www.cdc.gov/poxvirus/MPOX/interim-considerations/overview.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B40-viruses-16-01815"><label>40.</label><element-citation publication-type="gov"><article-title>Vaccines Licensed for Use in the United States|FDA</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B41-viruses-16-01815"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malone</surname><given-names>S.M.</given-names></name>
<name><surname>Mitra</surname><given-names>A.K.</given-names></name>
<name><surname>Onumah</surname><given-names>N.A.</given-names></name>
<name><surname>Brown</surname><given-names>A.</given-names></name>
<name><surname>Jones</surname><given-names>L.M.</given-names></name>
<name><surname>Tresvant</surname><given-names>D.</given-names></name>
<name><surname>Brown</surname><given-names>C.S.</given-names></name>
<name><surname>Onyia</surname><given-names>A.U.</given-names></name>
<name><surname>Iseguede</surname><given-names>F.O.</given-names></name>
</person-group><article-title>Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis</article-title><source>Int. J. Environ. Res. Public Health</source><year>2023</year><volume>20</volume><elocation-id>2963</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph20042963</pub-id><pub-id pub-id-type="pmid">36833653</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01815"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hazra</surname><given-names>A.</given-names></name>
<name><surname>Zucker</surname><given-names>J.</given-names></name>
<name><surname>Bell</surname><given-names>E.</given-names></name>
<name><surname>Flores</surname><given-names>J.</given-names></name>
<name><surname>Gordon</surname><given-names>L.</given-names></name>
<name><surname>Mitj&#x000e0;</surname><given-names>O.</given-names></name>
<name><surname>Su&#x000f1;er</surname><given-names>C.</given-names></name>
<name><surname>Lemaignen</surname><given-names>A.</given-names></name>
<name><surname>Jamard</surname><given-names>S.</given-names></name>
<name><surname>Nozza</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Mpox in people with past infection or a complete vaccination course: A global case series</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00492-9</pub-id><pub-id pub-id-type="pmid">37678309</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01815"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rasmussen</surname><given-names>S.A.</given-names></name>
<name><surname>Watson</surname><given-names>A.K.</given-names></name>
<name><surname>Kennedy</surname><given-names>E.D.</given-names></name>
<name><surname>Broder</surname><given-names>K.R.</given-names></name>
<name><surname>Jamieson</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Vaccines and pregnancy: Past, present, and future</article-title><source>Semin. Fetal Neonatal Med.</source><year>2013</year><volume>19</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.siny.2013.11.014</pub-id><pub-id pub-id-type="pmid">24355683</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01815"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>R.B.</given-names></name>
<name><surname>Ovsyannikova</surname><given-names>I.</given-names></name>
<name><surname>Poland</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Smallpox vaccines for biodefense</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><issue>(Suppl. S4)</issue><fpage>D73</fpage><lpage>D79</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.103</pub-id><pub-id pub-id-type="pmid">19837292</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01815"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Barrett</surname><given-names>A.D.T.</given-names></name>
<name><surname>Stanberry</surname><given-names>L.R.</given-names></name>
</person-group><source>Vaccines for Biodefense and Emerging and Neglected Diseases</source><publisher-name>Elsevier Inc.</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2008</year><fpage>527</fpage><lpage>535</lpage></element-citation></ref><ref id="B46-viruses-16-01815"><label>46.</label><element-citation publication-type="gov"><article-title>Mpox (Monkeypox) Vaccines|Australian Government Department of Health and Aged Care</article-title><comment>Available online: <ext-link xlink:href="https://www.health.gov.au/diseases/mpox-monkeypox/vaccines" ext-link-type="uri">https://www.health.gov.au/diseases/mpox-monkeypox/vaccines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B47-viruses-16-01815"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pittman</surname><given-names>P.R.</given-names></name>
<name><surname>Hahn</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>H.S.</given-names></name>
<name><surname>Koca</surname><given-names>C.</given-names></name>
<name><surname>Samy</surname><given-names>N.</given-names></name>
<name><surname>Schmidt</surname><given-names>D.</given-names></name>
<name><surname>Hornung</surname><given-names>J.</given-names></name>
<name><surname>Weidenthaler</surname><given-names>H.</given-names></name>
<name><surname>Heery</surname><given-names>C.R.</given-names></name>
<name><surname>Meyer</surname><given-names>T.P.</given-names></name>
<etal/>
</person-group><article-title>Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1897</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1817307</pub-id><pub-id pub-id-type="pmid">31722150</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01815"><label>48.</label><element-citation publication-type="webpage"><article-title>Health Canada Extends Approval of IMVAMUNE to Immunization</article-title><comment>Available online: <ext-link xlink:href="https://www.globenewswire.com/news-release/2020/11/12/2125193/0/en/Health-Canada-Extends-Approval-of-IMVAMUNE-to-Immunization-against-Monkeypox-and-Orthopox-Viruses.html" ext-link-type="uri">https://www.globenewswire.com/news-release/2020/11/12/2125193/0/en/Health-Canada-Extends-Approval-of-IMVAMUNE-to-Immunization-against-Monkeypox-and-Orthopox-Viruses.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B49-viruses-16-01815"><label>49.</label><element-citation publication-type="webpage"><article-title>Global Monkeypox Vaccine Race Sparks Fears That Poorer Nations Will Lose Out|Global Development|The Guardian</article-title><comment>Available online: <ext-link xlink:href="https://www.theguardian.com/global-development/2022/aug/01/global-monkeypox-vaccine-race-sparks-fears-that-poorer-nations-will-lose-out" ext-link-type="uri">https://www.theguardian.com/global-development/2022/aug/01/global-monkeypox-vaccine-race-sparks-fears-that-poorer-nations-will-lose-out</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B50-viruses-16-01815"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogunkola</surname><given-names>I.O.</given-names></name>
<name><surname>Abiodun</surname><given-names>O.E.</given-names></name>
<name><surname>Bale</surname><given-names>B.I.</given-names></name>
<name><surname>Elebesunu</surname><given-names>E.E.</given-names></name>
<name><surname>Ujam</surname><given-names>S.B.</given-names></name>
<name><surname>Umeh</surname><given-names>I.C.</given-names></name>
<name><surname>Tom-James</surname><given-names>M.</given-names></name>
<name><surname>Musa</surname><given-names>S.S.</given-names></name>
<name><surname>Manirambona</surname><given-names>E.</given-names></name>
<name><surname>Evardone</surname><given-names>S.B.</given-names></name>
<etal/>
</person-group><article-title>Monkeypox vaccination in the global south: Fighting a war without a weapon</article-title><source>Clin. Epidemiol. Glob. Health</source><year>2023</year><volume>22</volume><fpage>101313</fpage><pub-id pub-id-type="doi">10.1016/j.cegh.2023.101313</pub-id><pub-id pub-id-type="pmid">37220529</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01815"><label>51.</label><element-citation publication-type="webpage"><article-title>Race for Monkeypox Vaccines Exposes Global Health Inequality&#x02014;The Japan Times</article-title><comment>Available online: <ext-link xlink:href="https://www.japantimes.co.jp/news/2022/08/31/world/science-health-world/monkeypox-vaccine-distribution-inequality/" ext-link-type="uri">https://www.japantimes.co.jp/news/2022/08/31/world/science-health-world/monkeypox-vaccine-distribution-inequality/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B52-viruses-16-01815"><label>52.</label><element-citation publication-type="webpage"><article-title>Multi-Country Monkeypox Outbreak Declared a Global Public Health Emergency of International Concern&#x02014;Africa CDC</article-title><comment>Available online: <ext-link xlink:href="https://africacdc.org/news-item/multi-country-monkeypox-outbreak-declared-a-global-public-health-emergency-of-international-concern-2/" ext-link-type="uri">https://africacdc.org/news-item/multi-country-monkeypox-outbreak-declared-a-global-public-health-emergency-of-international-concern-2/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B53-viruses-16-01815"><label>53.</label><element-citation publication-type="webpage"><article-title>Support for Africa&#x02019;s Vaccine Production Is Good for the World</article-title><comment>Available online: <ext-link xlink:href="https://www.imf.org/en/Blogs/Articles/2022/01/12/blog011322-support-for-africas-vaccine-production-is-good-for-the-world" ext-link-type="uri">https://www.imf.org/en/Blogs/Articles/2022/01/12/blog011322-support-for-africas-vaccine-production-is-good-for-the-world</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B54-viruses-16-01815"><label>54.</label><element-citation publication-type="webpage"><article-title>Is There Any COVID-19 Vaccine Production in Africa?&#x02014;Carnegie Endowment for International Peace | Carnegie Endowment for International Peace</article-title><comment>Available online: <ext-link xlink:href="https://carnegieendowment.org/posts/2021/09/is-there-any-covid-19-vaccine-production-in-africa?lang=en" ext-link-type="uri">https://carnegieendowment.org/posts/2021/09/is-there-any-covid-19-vaccine-production-in-africa?lang=en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B55-viruses-16-01815"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schaefer</surname><given-names>G.O.</given-names></name>
<name><surname>Emanuel</surname><given-names>E.J.</given-names></name>
<name><surname>Atuire</surname><given-names>C.A.</given-names></name>
<name><surname>Leland</surname><given-names>R.</given-names></name>
<name><surname>Persad</surname><given-names>G.</given-names></name>
<name><surname>Richardson</surname><given-names>H.S.</given-names></name>
<name><surname>Saenz</surname><given-names>C.</given-names></name>
</person-group><article-title>Equitable global allocation of monkeypox vaccines</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>7084</fpage><lpage>7088</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.07.021</pub-id><pub-id pub-id-type="pmid">37460354</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01815"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fidler</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1</article-title><source>PLoS Med.</source><year>2010</year><volume>7</volume><elocation-id>e1000247</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000247</pub-id><pub-id pub-id-type="pmid">20454566</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01815"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tovani-Palone</surname><given-names>M.R.</given-names></name>
<name><surname>Doshi</surname><given-names>N.</given-names></name>
<name><surname>Pedersini</surname><given-names>P.</given-names></name>
</person-group><article-title>Inequity in the global distribution of monkeypox vaccines</article-title><source>World J. Clin. Cases</source><year>2023</year><volume>11</volume><fpage>4498</fpage><lpage>4503</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v11.i19.4498</pub-id><pub-id pub-id-type="pmid">37469745</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01815"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cernuschi</surname><given-names>T.</given-names></name>
<name><surname>Gilchrist</surname><given-names>S.</given-names></name>
<name><surname>Hajizada</surname><given-names>A.</given-names></name>
<name><surname>Malhame</surname><given-names>M.</given-names></name>
<name><surname>Mariat</surname><given-names>S.</given-names></name>
<name><surname>Widmyer</surname><given-names>G.</given-names></name>
</person-group><article-title>Price transparency is a step towards sustainable access in middle income countries</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>l5375</fpage><pub-id pub-id-type="doi">10.1136/bmj.l5375</pub-id><pub-id pub-id-type="pmid">31932333</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01815"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajkhowa</surname><given-names>P.</given-names></name>
<name><surname>Dsouza</surname><given-names>V.S.</given-names></name>
<name><surname>Kharel</surname><given-names>R.</given-names></name>
<name><surname>Cauvery</surname><given-names>K.</given-names></name>
<name><surname>Mallya</surname><given-names>B.R.</given-names></name>
<name><surname>Raksha</surname><given-names>D.S.</given-names></name>
<name><surname>Mrinalini</surname><given-names>V.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Pattanshetty</surname><given-names>S.</given-names></name>
<name><surname>Narayanan</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Factors Influencing Monkeypox Vaccination: A Cue to Policy Implementation</article-title><source>J. Epidemiol. Glob. Health</source><year>2023</year><volume>13</volume><fpage>226</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1007/s44197-023-00100-9</pub-id><pub-id pub-id-type="pmid">37119512</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01815"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhary</surname><given-names>O.P.</given-names></name>
<name><surname>Priyanka</surname></name>
<name><surname>Fahrni</surname><given-names>M.L.</given-names></name>
<name><surname>Saied</surname><given-names>A.A.</given-names></name>
<name><surname>Chopra</surname><given-names>H.</given-names></name>
</person-group><article-title>Ring vaccination for monkeypox containment: Strategic implementation and challenges</article-title><source>Int. J. Surg.</source><year>2022</year><volume>105</volume><fpage>106873</fpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106873</pub-id><pub-id pub-id-type="pmid">36055631</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01815"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
<name><surname>Kalra</surname><given-names>K.</given-names></name>
<name><surname>Phelan</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries</article-title><source>PLoS Glob. Public Health</source><year>2023</year><volume>3</volume><elocation-id>e0002098</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgph.0002098</pub-id><pub-id pub-id-type="pmid">37384623</pub-id>
</element-citation></ref><ref id="B62-viruses-16-01815"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emanuel</surname><given-names>E.J.</given-names></name>
<name><surname>Persad</surname><given-names>G.</given-names></name>
<name><surname>Kern</surname><given-names>A.</given-names></name>
<name><surname>Buchanan</surname><given-names>A.</given-names></name>
<name><surname>Fabre</surname><given-names>C.</given-names></name>
<name><surname>Halliday</surname><given-names>D.</given-names></name>
<name><surname>Heath</surname><given-names>J.</given-names></name>
<name><surname>Herzog</surname><given-names>L.</given-names></name>
<name><surname>Leland</surname><given-names>R.J.</given-names></name>
<name><surname>Lemango</surname><given-names>E.T.</given-names></name>
<etal/>
</person-group><article-title>An ethical framework for global vaccine allocation</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1309</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1126/science.abe2803</pub-id><pub-id pub-id-type="pmid">32883884</pub-id>
</element-citation></ref><ref id="B63-viruses-16-01815"><label>63.</label><element-citation publication-type="webpage"><article-title>COVID-19 Vaccinations Shift to Regular Immunization as COVAX Draws to a Close</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news/item/19-12-2023-covid-19-vaccinations-shift-to-regular-immunization-as-covax-draws-to-a-close" ext-link-type="uri">https://www.who.int/news/item/19-12-2023-covid-19-vaccinations-shift-to-regular-immunization-as-covax-draws-to-a-close</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-07">(accessed on 7 October 2024)</date-in-citation></element-citation></ref><ref id="B64-viruses-16-01815"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khairi</surname><given-names>L.N.H.M.</given-names></name>
<name><surname>Fahrni</surname><given-names>M.L.</given-names></name>
<name><surname>Lazzarino</surname><given-names>A.I.</given-names></name>
</person-group><article-title>The Race for Global Equitable Access to COVID-19 Vaccines</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1306</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10081306</pub-id><pub-id pub-id-type="pmid">36016194</pub-id>
</element-citation></ref><ref id="B65-viruses-16-01815"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lawrence</surname><given-names>A.</given-names></name>
<name><surname>Anejo-Okopi</surname><given-names>J.</given-names></name>
<name><surname>Adeseye</surname><given-names>B.</given-names></name>
</person-group><article-title>The Feasibility of Elimination of Monkeypox Virus in Nigeria: A Systematic Review</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e61867</fpage><pub-id pub-id-type="doi">10.7759/cureus.61867</pub-id><pub-id pub-id-type="pmid">38978921</pub-id>
</element-citation></ref></ref-list></back></article>